Forty Seven was a clinical-stage biotechnology company focused on developing cancer immunotherapies by targeting the CD47 pathway. Founded in 2014, the company's lead approach involved blocking CD47, a protein that serves as a 'don't eat me' signal that allows cancer cells to evade immune system detection. By inhibiting this pathway, Forty Seven's therapies aimed to enable macrophages and other immune cells to recognize and destroy cancer cells more effectively. The company developed magrolimab and other CD47-targeting therapeutics for various blood cancers and solid tumors. Gilead Sciences acquired Forty Seven in 2020 for $4.9 billion.
Forty Seven has received investment from 1 venture capital firm.
Biotechnology company developing cancer immunotherapies targeting the CD47 pathway to enhance immune system recognition of cancer cells.
Forty Seven has received investment from Versant Ventures. These venture capital firms and investors provide both capital and strategic support.
Forty Seven has raised $320M in total funding, with their most recent round being a Series C. The company operates in the Biotech sector.
Forty Seven was founded in 2014 and is headquartered in Menlo Park, California.
Forty Seven operates in the Biotech sector. Biotechnology company developing cancer immunotherapies targeting the CD47 pathway to enhance immune system recognition of cancer cells.
